Medical/Pharmaceuticals
Shin-Etsu SE Tylose and LBB Specialties Announce Distribution Partnership for Cellulose Pharma Excipients in North and Central America
NORWALK, Conn., Sept. 25, 2024 /PRNewswire/ -- LBB Specialties (LBBS), a leader in specialty chemicals and ingredient distribution inNorth America, announces a new partnership with SE TyloseUSA for cellulose excipients in the Pharma Excipients and Nutra Ingredients markets. EffectiveNovember 1, 2...
2024-09-25 22:00
1455
Rx-360 Announces Approval as a Pilot Center of Excellence for the APEC Regulatory Harmonization Steering Committee
PHILADELPHIA, Sept. 25, 2024 /PRNewswire/ -- Rx-360® is pleased to announce that it has been accepted as a Pilot Center of Excellence (CoE) for the APEC Regulatory Harmonization Steering Committee. The pilot will be focused on the Global Medical Product Supply Chain Integrity Priority Work Area R...
2024-09-25 21:09
1566
CariGenetics And One BioMed Strike Partnership to Advance Genomic Testing in the Caribbean - Decentralised Approach Serves the Needs of the Caribbean Community
HAMILTON, Bermuda, Sept. 25, 2024 /PRNewswire/ -- CariGenetics and One BioMed are proud to announce their strategic partnership to bring One BioMed's Xceler8 Platform across theCaribbean. Implementing this cutting-edge technology in the region marks a major advancement in the field ofCaribbean ge...
2024-09-25 19:00
1575
New Research from the International Coaching Federation Highlights Trends in Workplace Burnout
- Demand for mental well-being support becoming widespread - LEXINGTON, Ky., Sept. 25, 2024 /PRNewswire/ -- New research, released today by the International Coaching Federation (ICF), indicates growing workplace demand for mental well-being support. With mental well health concerns including b...
2024-09-25 17:00
1439
GSK's Arexvy is a vaccine approved to protect older adults from respiratory syncytial virus (RSV) disease in Malaysia
* Adults aged 60 and over with underlying co-morbidities are at high risk of developing severe infections from RSV * Vaccine showed 82.6% overall vaccine efficacy against RSV-LRTD with 94.6% efficacy observed in adults with co-morbidities vii KUALA LUMPUR, Malaysia, Sept. 25, 2024 /PRNewswire...
2024-09-25 16:45
1862
FONDAZIONE PRADA PRESENTS "PRESERVING THE BRAIN: A CALL TO ACTION" IN MILAN
MILAN, Sept. 25, 2024 /PRNewswire/ -- The new edition of "Preserving the Brain," part of Fondazione Prada's "Human Brains" project dedicated to neurosciences since 2018, will focus on the prevention of neurodegenerative diseases. Organized in partnership with fifteen renowned neuroscience instit...
2024-09-25 16:00
1297
Belief BioMed to Collaborate with AskBio to Explore the Potential of New Gene Therapies
* Belief BioMed and AskBio will work together to advance potential gene therapies in diseases with high unmet medical need, using a liver-targeted approach. SHANGHAI, Sept. 25, 2024 /PRNewswire/ -- Belief BioMed Inc. (BBM), a biotech company focusing on innovative gene therapies, today announce...
2024-09-25 14:58
1459
Biocon Biologics Announces New Dermatology Data to Be Presented at EADV Congress 2024
* Switching between adalimumab and adalimumab-fkjp in Phase 3 study in patients with chronic plaque psoriasis supports interchangeability between adalimumab and adalimumab-fkjp * Biosimilarity between Bmab 1200 and reference biologic-Ustekinumab in pivotal Phase 3 trial in patients with moder...
2024-09-25 13:21
1285
Get To Know Severe Asthma: The Chronic, Life-Threatening Condition Affecting 7-11% Adults In Asian Countries
KUALA LUMPUR, Malaysia, Sept. 25, 2024 /PRNewswire/ -- Asthma is well-known as a common respiratory condition. But did you know that there exists a life-threatening type of the condition calledsevere asthma, that requires specialised, multidisciplinary treatment to manage? Severe asthma is estim...
2024-09-25 11:00
1469
EADV Congress 2024: Semaglutide improves outcomes for obese patients with common skin condition, new study shows
A pioneering study, presented today at the EADV Congress 2024, demonstrates the significant potential of semaglutide in treating hidradenitis suppurative (HS), a common and chronic skin condition, in people with obesity. AMSTERDAM, Sept. 25, 2024 /PRNewswire/ -- This is the first study to explore...
2024-09-25 06:01
1344
EnGeneIC Selects Global CDMO BioCina to Advance Their Ground-Breaking Cancer Treatment
ADELAIDE, South Australia, Sept. 24, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced a new partnership with drug developer EnGeneIC Pty Ltd., for a project including technology transfer, process scale-up an...
2024-09-24 23:37
2024
Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
Veltassa® offers effective and well-tolerated long-term potassium control in chronic kidney disease and chronic heart failure patients1-5 Zeria Pharmaceutical Co., Ltd. to market Veltassa® in Japan ST. GALLEN, Switzerland, Sept. 24, 2024 /PRNewswire/ -- CSL Vifor today announced thatJapan's Mini...
2024-09-24 15:30
3027
BRIAN COX WARNS THE WORLD ABOUT WORKPLACE MENTAL HEALTH THREAT IN PSA FOR ASICS
Global study shows that our mental state starts to decline after only two hours of continuous desk-based working, but just 15 minutes of exercise can help to reverse the effects * ASICS enlists Brian Cox to take on the role of the world's scariest boss to highlight the real threat to our menta...
2024-09-24 07:01
1845
3B Scientific Acquires Veterinary Simulator Industries
HAMBURG, Germany, Sept. 23, 2024 /PRNewswire/ -- 3B Scientific, a global leader in the manufacturing and marketing of medical and scientific educational products, announced today that it has acquired Veterinary Simulator Industries (VSI), a leading developer of veterinary simulation models. Foun...
2024-09-23 18:00
1468
Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand
* XPOVIO® is the first and only approved XPO1 inhibitor in Thailand. * XPOVIO® has been approved for multiple indications in nine markets across the APAC region. Antengene has submitted a new drug application (NDA) for XPOVIO ® in Indonesia with approval expected in the second half of 2024. ...
2024-09-23 17:42
3451
Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics in East and South East Asia
* Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles inHong Kong and filed request for marketing authorization for Mainland China * Extension of Exclusive License and Distribution Agreement to include seven additional countries across East andS...
2024-09-23 15:00
1625
Huawei Launches Medical Technology Digitalization 2.0 Solution, Facilitating Precision Healthcare with AI
SHANGHAI, Sept. 23, 2024 /PRNewswire/ -- At HUAWEI CONNECT 2024, Huawei teamed up with partners to launch the Medical Technology Digitalization 2.0 Solution at the healthcare session namedEnhancing Inclusivity to Amplify Healthcare Intelligence. This solution implements AI-assisted diagnosis and ...
2024-09-23 12:10
4302
Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
MELBOURNE, Australia, INDIANAPOLIS and LAKE MARY, Fla., Sept. 23, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RLS (USA) Inc. (RLS, RLS Radiopharmacies), America's only Joint Commission-accredited radiopharmacy network distributing PET[1], SPECT[2] and th...
2024-09-23 07:38
1618
Summit of Whose Future? Girls Have the Answers: Leaders Must Listen
Young Women Activists Launch "What Girls Want," Demand World Leaders Put Girls at the Center of Summit of the Future NEW YORK, Sept. 21, 2024 /PRNewswire/ -- Today in New York, more than 50 young women from around the world – including Nobel Prize Laureate Malala Yousafzai – gathered to take go...
2024-09-21 21:30
2384
Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
* HANSIZHUANG (serplulimab) is the world's first anti-PD-1 mAb for first-line treatment of ES- SCLC - * HANSIZHUANG (serplulimab) is expected to become the first and only anti-PD-1 monoclonal antibody available inEurope for first-line treatment of ES- SCLC - * HANSIZHUANG (serplulimab) ha...
2024-09-21 13:42
4260
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8288
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7685